9823 Capital’s Axsome Therapeutics AXSM Stock Holding History

9823 Capital’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,215	Closed	-$222K	–	49
2025 Q4	$222K	Buy	+1,215	New	+$170K	0.15%	40

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

9823 Capital's AXSM Position: Q1 2026 in Review

9823 Capital sold out of Axsome Therapeutics (AXSM) in Q1 2026, closing a stake of 1,215 shares — an estimated $222K sold.

9823 Capital first reported a position in AXSM in Q4 2025 and held it in 1 quarter. The position peaked at $222K in Q4 2025. 410 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

9823 Capital reported no remaining Axsome Therapeutics position as of Q1 2026 after selling out during the quarter.
9823 Capital sold 1,215 Axsome Therapeutics shares in Q1 2026, an estimated $222K.
9823 Capital first reported a position in Axsome Therapeutics in Q4 2025 and held it in 1 quarter.
9823 Capital's Axsome Therapeutics position peaked at $222K in Q4 2025.
410 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on 9823 Capital's 13F filing for Q1 2026, filed 15 May 2026.